Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Lu G, Pine P, Leeds JM, DeGuzman F, Pratikhya P, Lin J, Malinowski J, Hollenbach SJ, Curnutte JT, Conley PB.

PLoS One. 2018 Mar 28;13(3):e0195122. doi: 10.1371/journal.pone.0195122. eCollection 2018.

2.

The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.

Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U.

J Pharmacol Exp Ther. 2014 Dec;351(3):538-48. doi: 10.1124/jpet.114.218164. Epub 2014 Sep 24.

PMID:
25253883
3.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U.

Nat Med. 2013 Apr;19(4):446-51. doi: 10.1038/nm.3102. Epub 2013 Mar 3.

PMID:
23455714
4.

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM.

J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7.

5.

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.

Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, Hollenbach SJ, Phillips DR, Sinha U.

J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31.

PMID:
22040680
6.

Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding.

André P, DeGuzman F, Haberstock-Debic H, Mills S, Pak Y, Inagaki M, Pandey A, Hollenbach S, Phillips DR, Conley PB.

J Pharmacol Exp Ther. 2011 Jul;338(1):22-30. doi: 10.1124/jpet.110.178574. Epub 2011 Mar 29.

PMID:
21447613
7.

PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, McKenzie SE.

Blood. 2011 Feb 17;117(7):2241-6. doi: 10.1182/blood-2010-03-274969. Epub 2010 Nov 18.

8.

Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling.

Nanda N, Andre P, Bao M, Clauser K, Deguzman F, Howie D, Conley PB, Terhorst C, Phillips DR.

Blood. 2005 Nov 1;106(9):3028-34. Epub 2005 Jul 21.

9.

P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.

Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB.

J Clin Invest. 2003 Aug;112(3):398-406.

10.

A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V.

Ramakrishnan V, DeGuzman F, Bao M, Hall SW, Leung LL, Phillips DR.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1823-8.

11.

Ultrastructural analysis of megakaryocytes in GPV knockout mice.

Poujol C, Ramakrishnan V, DeGuzman F, Nurden AT, Phillips DR, Nurden P.

Thromb Haemost. 2000 Aug;84(2):312-8.

PMID:
10959706
12.

Increased thrombin responsiveness in platelets from mice lacking glycoprotein V.

Ramakrishnan V, Reeves PS, DeGuzman F, Deshpande U, Ministri-Madrid K, DuBridge RB, Phillips DR.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13336-41.

13.

Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function.

Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR.

Nature. 1999 Oct 21;401(6755):808-11.

PMID:
10548108

Supplemental Content

Loading ...
Support Center